Key result
BNT162b2 vaccination is linked to new-onset POTS in a healthy 46-year-old female.
Why the study?
There have been few reports of new-onset postural orthostatic tachycardia syndrome after COVID-19 vaccination, and further study is needed to understand prevalence, etiology, and management.
Does the BNT162b2 SARS-CoV-2 vaccine induce postural orthostatic tachycardia syndrome in healthy individuals?
Case Report (n=1)
Does the BNT162b2 SARS-CoV-2 vaccine induce postural orthostatic tachycardia syndrome in healthy individuals?
This case report highlights a potential rare adverse event of new-onset POTS following COVID-19 vaccination, suggesting a need for clinical awareness.
Raises awareness for possible post-vaccination POTS; leaves open causality in healthy adults.
We report a case of new-onset postural orthostatic tachycardia syndrome in a healthy 46-year-old female after a single dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. There have been three prior reports of new-onset postural orthostatic tachycardia syndrome after COVID-19 vaccination. Predominant symptoms noted included fatigue, brain fog, headache, sinus tachycardia, and dizziness. Management includes noninvasive therapies, behavioral approaches, and pharmacologic regimens. Here, the patient presented with fatigue, palpitations, dizziness, and presyncope, with symptoms beginning 7 days after vaccination. Presenting vitals included temperature within normal limits, inappropriate tachycardia, up to 120 beats per minute, blood pressure of 128/87 mm of mercury, and 100% saturation in room air. Her management included lifestyle changes, dietary supplements, and ivabradine. Further studies are needed to evaluate prevalence, etiology, and optimal management.
No takes yet. Share an insight, caveat, or question.
Hermel et al. (2022) conducted a case report in postural orthostatic tachycardia syndrome (n=1). BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine was evaluated on postural orthostatic tachycardia syndrome. A healthy 46-year-old female developed new-onset postural orthostatic tachycardia syndrome 7 days after receiving a single dose of the BNT162b2 SARS-CoV-2 vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: